Fides Pharma is an early-clinical stage biotech company dedicated to the development of fully human monoclonal antibodies for the prophylaxis and treatment of influenza viruses and hepatitis C virus.

The company can benefit from high quality research and a proven R&D track record of San Raffaele Institute, Center of Excellence of the North of Italy, recognized worldwide.

The company inherited the high quality research and the relevant clinical trials track record of San Raffaele Institute, Center of Excellence of the North of Italy recognized worldwide, thanks to its scientists originators, Prof. Massimo Clementi, Professor of Microbiology and Virology and Dean of the School of Medicine of the Università Vita-Salute San Raffaele, and Professor Roberto Burioni, Associate of Microbiology and Virology at the same University.

Fides Pharma pipeline comprises of four fully human mAbs, two for HCV and two for influenza. All these mAbs showed compelling neutralizing properties over a broad ranges of viruses subtypes with very interesting IC50 values making them “best in class” mAbs for the two target indications.

All mAbs have been in-licensed from Pomona Ricerca, a platform company that benefits from the experience of its lead scientists, Prof Clementi and Prof Burioni, who are among the key opinion leaders in the field of the human immune response against human pathogens and host-pathogen interplay.

The inspiring scientists and originators of Fides Pharma, Professor Massimo Clementi (link), Professor of Microbiology and Virology and Dean of the School of Medicine of the Università Vita-Salute San Raffaele, and Professor Roberto Burioni (link), Associate of Microbiology and Virology at the same University, are internationally recognized experts  in the field of human monoclonal antibodies and in the research of  the host-pathogen interplay, with an outstanding publication track in this field.

From its incorporation, in December 2010, Fides Pharma has been financed by angel investors.

Board of directors: Leandro Burgay (President), Silvana Ginevro (CEO)
Scientific Advisory Board: Prof. Massimo Clementi, Prof. Roberto Burioni, Prof. Gianni Garotta